research Cutaneous Adverse Events of Targeted Anticancer Therapy: A Review of Common Clinical Manifestations and Management
Targeted anticancer therapies often cause skin issues, affecting treatment adherence and quality of life.
Search
for
Sort by
Research
840-870 / 1000+ resultsresearch Caffeine ameliorates radiation-induced skin reactions in mice but does not influence tumour radiation response
Caffeine reduces radiation skin damage but doesn't affect tumor treatment.
research Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
research Synthesis of avicequinone c and analogs toward the study of 5α-reductase inhibitory activity
2-Hydroxy-1,4-naphthoquinone is a strong 5α-reductase inhibitor.
research A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes
Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
research USE OF TOFACITINIB IN DIFFICULT TO TREAT CLINICALLY AMYOPATHIC DERMATOMYOSITIS
Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
research Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.
research Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
research Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy
Doxil is an effective, modified chemotherapy drug with a unique toxicity profile and shows promise in treating certain cancers.
research Probing androgen receptor co-factor selectivity profiles: a chemical tool to determine cross-talk between androgen receptor and β-catenin in vivo
PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
research Upadacitinib for the treatment of alopecia areata – A case report
Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.
research Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series
Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
research Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects
The cancer drugs bortezomib and lenalidomide cause skin side effects in many patients.
research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
research Antitumour and toxic effects on Wistar rats of two new platinum complexes
The new platinum complexes effectively increased survival in rats with tumors, despite some reversible side effects.
research Finasteride Tablets
research Finasteride Tablets
research Topical minoxidil and dietary supplement for the treatment of chemotherapy-induced alopecia in childhood: a retrospective cohort study
Topical minoxidil and dietary supplements improved hair regrowth in children with hair loss from chemotherapy.
research Acute and Long-term Toxicity of Cyclophosphamide
Cyclophosphamide can cause serious short-term and long-term side effects, including increased cancer risk and infertility.
research Baricitinib in Alopecia Areata: Real-Life Changes in Lipid Profile and Hematologic Inflammation Indices at 52 weeks
Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.
research Alopecia areata flare patterns in children and young adults while on systemic tofacitinib
Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
research 3D Microtumors Representing Ovarian Cancer Minimal Residual Disease Respond to the Fatty Acid Oxidation Inhibitor Perhexiline
Perhexiline can effectively target ovarian cancer cells left after treatment.
research Methotrexate for induction of remission in ulcerative colitis
Methotrexate is not proven effective for inducing remission in ulcerative colitis.
research Evaluation of hydro-alcoholic extract of Eclipta alba for its anticancer potential: An in vitro study
Eclipta alba extract shows potential as an anticancer agent by inhibiting cancer cell growth and promoting cell death.
research Efficacy of Scalp Cooling System Versus Chemical Cooling Cap in Preventing Chemotherapy-induced Alopecia in Breast Cancer (COHAIR Study): a prospective randomized trial
Both scalp cooling and chemical cooling caps effectively prevent hair loss in breast cancer patients undergoing chemotherapy.
research Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment
Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.
research Systemic Tofacitinib in Alopecia Areata: A Single Center Retrospective Descriptive Cohort Study
Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
research 699 Pharmacological blockade of the CX3CR1/CX3CL1 fractalkine axis prevents alopecia areata in C3H/HeJ mice
research Drug Survival and Long-term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study
Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.
research A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis
Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.